ST-920 Gene Therapy Continues to Show Safety, Efficacy in Trial

ST-920 Gene Therapy Continues to Show Safety, Efficacy in Trial

321668

ST-920 Gene Therapy Continues to Show Safety, Efficacy in Trial

Updated findings in an ongoing Phase 1/2 clinical trial of Sangamo Therapeutics‘ gene therapy ST-920 (isaralgagene civaparvovec) shows the treatment continues to be well tolerated and effective in adults with Fabry disease. As of the Nov. 19 data cutoff date, all five treated patients enrolled showed normalized levels of alpha-GalA — the enzyme lacking in those with Fabry — and has been sustained for at least a year in the longest treated patients. The trial, called…

You must be logged in to read/download the full post.